BioGaia AB (CHIX:BIOGBS) EBIT: kr429 Mil (TTM As of Mar. 2026)


CHIX:BIOGBS BioGaia AB CHIX:BIOGBS
100 GF Score
Price kr120.20
GF Value kr129.06
! 4 Warning Signs
View Full Analysis

What is BioGaia AB EBIT?

BioGaia AB CHIX:BIOGBS 100 EBIT is kr429 Mil as of Mar. 2026. GuruFocus rates CHIX:BIOGBS with a GF Score™ of 100/100 and a GF Value™ of kr129.06. The stock has 4 warning signs investors should review.

BioGaia AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr103 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr429 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioGaia AB's annualized ROC % for the quarter that ended in Mar. 2026 was 40.75%. BioGaia AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 109.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioGaia AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.85%.

BioGaia AB  (CHIX:BIOGBs) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioGaia AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=404.616 * ( 1 - 21.77% )/( (730.709 + 822.863)/ 2 )
=316.5310968/776.786
=40.75 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1597.807 - 65.788 - ( 801.31 - max(0, 199.142 - 1219.074+801.31))
=730.709

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1694.645 - 0 - ( 871.782 - max(0, 266.485 - 1315.832+871.782))
=822.863

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

BioGaia AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=413.996/( ( (181.151 + max(217.606, 0)) + (176.828 + max(177.565, 0)) )/ 2 )
=413.996/( ( 398.757 + 354.393 )/ 2 )
=413.996/376.575
=109.94 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(216.168 + 166.704 + 33.876) - (65.788 + 0 + 133.354)
=217.606

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 444.05) - (0 + 0 + 266.485)
=177.565

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioGaia AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=429.148/11146.300
=3.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB EBIT Related Terms

BioGaia AB EBIT Historical Data

* Premium members only.

The historical data trend for BioGaia AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB EBIT Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 253.84 453.00 469.64 449.26 427.28

BioGaia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.02 112.93 88.91 123.81 103.50

CHIX:BIOGBS vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGaia AB EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioGaia AB's EV-to-EBIT falls into.


CHIX:BIOGBS
100GF Score
BioGaia AB CHIX:BIOGBS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr429 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr429 Mil mean?
BioGaia AB (CHIX:BIOGBS) has a EBIT of kr429 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioGaia AB.
Is BioGaia AB's EBIT too high?
BioGaia AB's current EBIT is kr429 Mil. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's EBIT compare to ZTS?
BioGaia AB's EBIT of kr429 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioGaia AB. BioGaia AB's current EBIT is kr429 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (CHIX:BIOGBS) has a current EBIT of kr429 Mil. The stock's GF Value™ is kr129.06, compared to a current price of kr120.20 — trading 6.9% below its estimated fair value. The current EBIT is kr429 Mil. BioGaia AB's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BioGaia AB (CHIX:BIOGBS), the current EBIT is kr429 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (CHIX:BIOGBS) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of kr120.20 is trading 6.9% below its estimated GF Value™ of kr129.06.

Key valuation signals for CHIX:BIOGBS:

  • EBIT: kr429 Mil
  • GF Value™: kr129.06 vs. price of kr120.20 (6.9% below fair value)
  • GF Score™: 100/100 with 4 warning signs

No single metric tells the full story. See the CHIX:BIOGBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for CHIX:BIOGBS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr120.20
Price
kr129.06
GF Value